81 related articles for article (PubMed ID: 27408334)
1. Review: The PI3K-AKT-mTOR signal transduction pathway in canine cancer.
Meuten TK; Dean GA; Thamm DH
Vet Pathol; 2024 May; 61(3):339-356. PubMed ID: 37905509
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-8 promotes canine hemangiosarcoma growth by regulating the tumor microenvironment.
Kim JH; Frantz AM; Anderson KL; Graef AJ; Scott MC; Robinson S; Sharkey LC; O Brien TD; Dickerson EB; Modiano JF
Exp Cell Res; 2014 Apr; 323(1):155-164. PubMed ID: 24582862
[TBL] [Abstract][Full Text] [Related]
3. VDX-111 targets proliferative pathways in canine cancer cell lines.
Farrell KB; Das S; Nordeen SK; Lambert JR; Thamm DH
PLoS One; 2024; 19(5):e0303470. PubMed ID: 38771847
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal administration of synthetic microRNA-214 elicits tumor suppression in an intraperitoneal dissemination mouse model of canine hemangiosarcoma.
Yoshikawa R; Maeda A; Ueno Y; Sakai H; Kimura S; Sawadaishi T; Kohgo S; Yamada K; Mori T
Vet Res Commun; 2022 Jun; 46(2):447-457. PubMed ID: 34988875
[TBL] [Abstract][Full Text] [Related]
5. Current understanding of comparative pathology and prospective research approaches for canine hemangiosarcoma.
Suzuki T; Henshaw MJ; Yanagi T; Aoshima K
Res Vet Sci; 2024 Feb; 167():105120. PubMed ID: 38150941
[TBL] [Abstract][Full Text] [Related]
6. Establishment and characterization of six canine hepatocellular carcinoma cell lines.
Lee JY; Bae K; Kim JH; Han HJ; Yoon HY; Yoon KA
Front Vet Sci; 2024; 11():1392728. PubMed ID: 38840628
[TBL] [Abstract][Full Text] [Related]
7. Pathobiology of Hemangiosarcoma in Dogs: Research Advances and Future Perspectives.
Kim JH; Graef AJ; Dickerson EB; Modiano JF
Vet Sci; 2015 Nov; 2(4):388-405. PubMed ID: 29061949
[TBL] [Abstract][Full Text] [Related]
8. Parthenolide As a Therapeutic for Disseminated Canine Neoplasms.
Schlein LJ; Brill SA; Brady RV; Farrell KB; Rose BJ; Meuten TK; Jordan CT; Thamm DH
J Pharmacol Exp Ther; 2024 Feb; 388(3):774-787. PubMed ID: 38135509
[TBL] [Abstract][Full Text] [Related]
9. Retrospective Study of Clinicopathological Changes and Prediction Model for Canine Vascular Neoplasms.
Suphonkhan J; Klaymongkol C; Khomsiri W; Wanprom J; Jeamsripong S; Chimnakboon N; Rungsipipat A; Radtanakatikanon A
Vet Sci; 2024 Apr; 11(5):. PubMed ID: 38787161
[TBL] [Abstract][Full Text] [Related]
10. Hemangiosarcoma in dogs as a potential non-rodent animal model for drug discovery research of angiosarcoma in humans.
Heishima K; Aketa N; Heishima M; Kawachi A
Front Oncol; 2023; 13():1250766. PubMed ID: 38130992
[TBL] [Abstract][Full Text] [Related]
11. Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple Myeloma.
Sun K; Jin L; Karolová J; Vorwerk J; Hailfinger S; Opalka B; Zapukhlyak M; Lenz G; Khandanpour C
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190302
[TBL] [Abstract][Full Text] [Related]
12. Roles of GFPT2 Expression Levels on the Prognosis and Tumor Microenvironment of Colon Cancer.
Ding X; Liu H; Yuan Y; Zhong Q; Zhong X
Front Oncol; 2022; 12():811559. PubMed ID: 35330716
[TBL] [Abstract][Full Text] [Related]
13. Investigation of the effects of mTOR inhibitors rapamycin and everolimus in combination with carboplatin on canine malignant melanoma cells.
Bernard S; Poon AC; Tam PM; Mutsaers AJ
BMC Vet Res; 2021 Dec; 17(1):382. PubMed ID: 34895222
[TBL] [Abstract][Full Text] [Related]
14. The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside.
Feng Y; Chen X; Cassady K; Zou Z; Yang S; Wang Z; Zhang X
Front Oncol; 2020; 10():611690. PubMed ID: 33489922
[TBL] [Abstract][Full Text] [Related]
15. Angiosarcoma: a review of diagnosis and current treatment.
Cao J; Wang J; He C; Fang M
Am J Cancer Res; 2019; 9(11):2303-2313. PubMed ID: 31815036
[TBL] [Abstract][Full Text] [Related]
16. In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma.
Pyuen AA; Meuten T; Rose BJ; Thamm DH
PLoS One; 2018; 13(7):e0200634. PubMed ID: 30011343
[TBL] [Abstract][Full Text] [Related]
17. Combining the mammalian target of rapamycin inhibitor, rapamycin, with resveratrol has a synergistic effect in multiple myeloma.
Jin HG; Wu GZ; Wu GH; Bao YG
Oncol Lett; 2018 May; 15(5):6257-6264. PubMed ID: 29731844
[TBL] [Abstract][Full Text] [Related]
18. Actionable mutations in canine hemangiosarcoma.
Wang G; Wu M; Maloneyhuss MA; Wojcik J; Durham AC; Mason NJ; Roth DB
PLoS One; 2017; 12(11):e0188667. PubMed ID: 29190660
[TBL] [Abstract][Full Text] [Related]
19. Effects of inhibitors of vascular endothelial growth factor receptor 2 and downstream pathways of receptor tyrosine kinases involving phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin or mitogen-activated protein kinase in canine hemangiosarcoma cell lines.
Adachi M; Hoshino Y; Izumi Y; Sakai H; Takagi S
Can J Vet Res; 2016 Jul; 80(3):209-16. PubMed ID: 27408334
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
